Abstract. Hypermethylation of CpG islands is the most well defined epigenetic change in neoplasia and plays an important role in the inactivation or silencing of cancer related genes. DLX genes (1-7), with large CpG islands in their 5' region, are implicated in a number of processes among which haematopoiesis. They are characterized by highly dynamic spatiotemporal expression and supposed to be involved in resistance to apoptosis of several tumor cell lines. In acute lymphoblastic leukemia (ALL) hypermethylation is a common phenomenon frequently associated with poor prognosis in specific genetic childhood leukemia subgroups. These data together with the presence of large CpG islands in the up-stream regions of the DLX genes make them attractive candidates for methylation regulated gene expression and leukemia related aberrancies. To validate the role of DLX genes in paediatric B-ALL cells, we studied two cell lines and two groups of patients with paediatric chromosomal rearrangements: MLL-AF4 and TEL-AML1, respectively. Analysis of methylation and gene expression patterns of DLX3 in 64 specimens of B-lineage ALL revealed that DLX3 presents aberrant methylation in paediatric B-ALL patients. In vitro experiments with 5-Aza-2'dC on leukemia cell lines, confirmed by Western blot analysis, indicated that the methylation of DLX3 CpG islands has a functional role and interferes with the DLX3 gene and DLX3 protein expression in B-ALL cells. Importantly, hypermethylation of DLX3 significantly reduces its expression in MLL-AF4 rearranged leukemias while methylation is almost absent in TEL-AML1 positive ALL specimens. These results show that differential DLX3 methylation could be a new epigenetic marker for genotypic B-cell leukemia subgroup with high-risk features.
Introduction
Chromosomal translocations that inactivate or create new fusion genes are a common hallmark of acute lymphoblastic leukemia (ALL) and may serve as diagnostic and prognostic markers in subtypes of ALL (1, 2) . However, translocations alone do not result in leukemeogenesis; other aberrancies that are either the consequence of the translocation or an independent secondary event have to occur before leukemia develops (3) . It has been demonstrated that aberrant methylation of clustered cytosine-guanosine motifs (CpG), especially in CpG islands located in gene promoter regions, is an early and essential step in tumor development and methylation has been proved to be a mechanism of gene silencing as common as the disruption of tumor-suppressor genes by mutation or deletion (4) (5) (6) . Moreover, DNA hypermethylation and transcriptional silencing of genes involved in tumor invasiveness, cell growth and apoptosis, may also influence recurrence after treatment and overall survival. Inactivation of cancer-related genes by DNA methylation is a frequent event also in paediatric and adult ALL and, by looking at differences in the methylation pattern of multiple genes, specific risk groups among patients have been identified (7) . It is understood that each type of cancer may have several genes susceptible to promoter hypermethylation and individual tumors would exhibit different frequencies of hypermethylation patterns of multiple genes, eventually related to patient's clinical outcome (8, 9) . No systematic identification of aberrant genomic methylation of neoplasias or leukemias has so far been performed while several studies have focused on silencing of specific genes in specific subtypes of leukemias (10, 11) . The identification of novel DNA methylation-based prognostic indicators requires the selection of suitable candidate genes.
The DLX genes (DLX1-7) implicated in haematopoiesis and in a number of other processes with highly dynamic spatio-temporal expression patterns (12) and well-defined CpG islands in their promoter region, are attractive targets for methylation studies in leukemia subtypes. In particular, the down-regulation of DLX2, 3 and 4 has been described in a group of paediatric B-ALL characterized by the t(4;11) (MLL-AF4) chromosomal rearrangement (13) . Furthermore, it has been reported that this down-regulation is directly connected to an increased resistance to apoptosis in several cancer cell lines (14) . The presence of extended CpG islands at the 5'-end of DLX2, 3 and 4 genes, their possible role in resistance to apoptosis, and the recent finding of DLX5 promoter methylation as one of the epigenetic markers of chronic lymphoblastic leukemia (CLL) (15) , prompted us to study the methylation and gene expression pattern of DLX2, 3 and 4 in specific paediatric ALL subtypes. Among the paediatric ALL, there are two fundamental subtypes: the first is that of B-ALL carrying the t(4;11) (q21;q23)(MLL-AF4) rearrangement present in the 3% of paediatric leukemia and in 70% of infants (16) ; the second is represented by B-ALL carrying the t(12;21) (p13;q22)(TEL-AML1) chromosomal aberration that, rare in adult B-ALL, is the most frequent (25-30%) in childhood lymphoblastic leukemia (17) (18) (19) .
We analyzed the methylation status of DLX genes in cell lines representative of specific leukemic sub-types and the effect of demethylation on their gene expression. The remarkable DLX3 methylation-dependent inactivation, supported by reduced DLX3 protein expression, prompted our study on the DLX3 gene. To determine if the methylation status of DLX3 could identify two leukemia sub-types, we analyzed DLX3 CpG island methylation and gene expression in a group of paediatric B-ALL characterized by MLL-AF4 chromosomal rearrangement, and compared these with TEL-AML1 positive childhood patients; besides we used a more heterogeneous population of B-ALL without the abovementioned chromosomal alterations, as control group. Demonstrating that DLX3 methylation has a functional role in regulation of the DLX3 expression, DLX3 silencing in RS4;11 cell lines have been reversed treating cells with DNMT1 (DNA methyltransferase 1) inhibitor. Downregulation of DLX3 expression in relation to methylation has also been confirmed in paediatric B-ALL where DLX3 is significantly down-regulated in DLX3 promoter methylated specimens. Further-more we showed that DLX3 has the highest percentage of methylation and the lowest gene expression in MLL-AF4 positive B-ALL when compared to TEL-AML1 and control not-translocated specimens. Cell lines were maintained in RPMI-1640 (Biochrom AG, Germany) 10% FBS, incubated at 37˚C and 5% CO 2 and with penicillin (100 U/ml) and streptomycin (100 μg/ml).
Materials and methods

Leukemic
Leukemic and normal samples. The clinical samples utilized in our study were bone marrow aspirates (BM) or peripheral blood (PB) lymphocytes collected from 64 paediatric B-ALL patients from the Department of Paediatrics of Padua. This study was conducted after obtaining the informed consent from all patients following the tenets of the Declaration of Helsinki and was approved by the ethics committees of the participating institutions before the initiation of the study. Out of these, 34 were t(4;11)(q21;q23)(MLL-AF4) leukemias; 17 were t(12;21)(p13;q22)(TEL-AML1) positive. The remaining 13 samples lacked t(4;11) and t(12;21) translocations; moreover they lacked the other rearrangements t(1;19)(q23;p13)(E2A-PBX1) and t(9;22)(q34;q11)(BCR-ABL) routinely screened for the diagnosis of paediatric B-ALL. In all cases the percentage of blast cells ranged from 60 to 97%. Molecular diagnosis of t(4;11) and t(12;21) aberrations were accomplished following protocols defined by BIOMED-1 Concerted Action (20) . All patients were risk-stratified according to the therapeutic protocol based on standard prognostic features. As normal control samples we utilized a pool of five PB lymphocytes (PBL), a healthy BM aspirate and CD19 + cells isolated from a healthy donor as representative of normal B cells. Mononuclear cells from patients, PB and healthy BM were isolated using Ficoll-Hypaque (Pharmacia-LKB, Uppsala, Sweden) density gradient centrifugation. CD19 + B cells were separated from control PB with CD19 micro-beads (Miltenyi Biotec Inc., USA) according to manufacturer's instructions; the purity was consistently over 95%, as determined by flow cytometry analysis.
Treatment of leukemia cell lines with 5-Aza-2'dC. To achieve demethylation, RS4;11 and REH cell lines were treated with 5-Aza-2'-deoxycytidine (Sigma-Aldrich, St. Louis, MO, USA) at a concentration of 5 μM for 72 h. The 5-Aza-2'-deoxycytidine (5-Aza-2'-dC) containing culture medium was refreshed daily. Treated cells were harvested after 24, 48 and 72 h of incubation to extract DNA for methylation-specific PCR (MSP) analysis, total-RNA for real-time RQ-PCR and proteins for Western blot (WB) analysis as described below.
DNA and RNA extraction, and cDNA synthesis. Genomic DNA and total-RNA from cell lines and patients were extracted using a Purogene Kit (Gentra, MN, USA) and TRIzol reagent (Invitrogen, Karlsruhe, Germany) respectively. Total-RNA quality was verified using the Agilent Bioanalyzer 2100 and the Agilent RNA 6000 Nano Assay kit (Agilent Technologies, Waldbronn, Germany). RNA was then reverse-transcribed: 1 μg of total-RNA was incubated with random primers (Invitrogen) for 10 min at 70˚C and subsequently subjected to reverse transcription for 10 min at 25˚C and 30 min at 42˚C, followed by heating at 99.9˚C for 5 min. Reactions were performed in a final volume of 20 μl.
Sodium bisulfite modification of DNA and methylationspecific polymerase chain reaction (MSP).
Methylation analysis was carried out by methylation specific PCR (MSP) as previously described (21) . Briefly, DNA was treated with sodium bisulfite for 16 h at 50˚C to convert the unmethylated cytosines (C) to uracil leaving the methylated C unmodified. After purification the DNA was subjected to DNA amplification with primer sets recognizing solely the methylated or the unmethylated target and the PCR products were resolved on a 3% agarose 1000 gel (Invitrogen). The presence of amplification bands only with one set of primers indicates complete methylation (or unmethylation), whereas the amplification with both sets of primers is indicative of partial methylation (hemi-methylation).
Bisulfite modified DNA was used as template for MSP to analyze the methylation pattern of DLX2, DLX3 and DLX4 5' regions with specific primers (Table I ). The availability of DNA allowed the MSP analysis on 59 of the 64 patients included in this study. Primers were designed in the CpGrich regions -1000 bp to 500 bp relative to the beginning of the genes (Fig. 1) .
Exon/intron organization was deduced by aligning the reference sequences NM_004405 (DLX2), NM_005220 (DLX3) and NM_138281 (DLX4) on the human genome sequence. The transcription start of DLX3 was deduced by homology searching with the murine mRNA reference sequence for DLX3 (NM_010055). The start of transcription of the DLX4 gene has been independently identified (22) . CpG islands were located with the CPGPLOT software (http://bioweb.pasteur.fr/seqanal/interfaces/cpgplot.html). All MSP analyses were performed using CpGenome Universal Methylated DNA (UMD) (Chemicon, Temecula, CA) as positive control for methylated alleles and bone marrow (BM) from a normal donor as positive control for unmethylated alleles.
Real-time quantitative analysis. The mRNA expression levels of DLX3 and DLX4 were quantified by SYBR Green real-time quantitative PCR (RQ-PCR), using specific primers (Table II and Fig. 1 ) and the housekeeping gene Gus-B, glucuronidase-ß, as reference. Primers were designed using Primer Express software (Applied Biosystems, Foster City, CA). RQ primers for DLX4 were designed to detect all known splicing variants of DLX4. Reactions were performed in a final volume of 25 μl, containing 2 μl of cDNA, 12.5 μl of Platinum SYBR Green qPCR SuperMix-UDG 2X (Invitrogen, Life Technologies Inc., CA), and 0.5 μl of ROX reference dye. Reactions were performed on ABI PRISM 7700 SDS Table I . DLX2, DLX3 and DLX4 primer sequences used for MSP analysis. 
Fw, forward primer; Rv, reverse primer, M, primers for the methylated allele; U, primers for the unmethylated allele. Annealling temperature (˚C) and each MSP product length (bp) are also reported. (Applied Biosystems). Thermal cycler conditions were: a first hold of 2 min at 50˚C, followed by a denaturising step of 2 min at 90˚C and then by 50 cycles at 95˚C (15 sec for cycle) and 60˚C (30 sec for cycle). To exclude the contamination of unspecific PCR products such as primer dimers, melting curve analysis was applied to final PCR products after the cycling protocol. The expression levels of the target genes DLX3 and DLX4 and the reference gene Gus-B were determined from the calibration curve using the following equation: Amount=10^((C t -intercept)/slope). The target gene amount was then divided by the reference gene amount to obtain a normalized target value. The normalized gene target expressions were also calculated for un-treated RS4;11 cells lines (calibrator). Each of the cell-line/specimen-normalized gene target value was then divided by the calibrator-normalized gene target value to generate the final relative expression.
Protein extraction and Western blot analysis. Cells were solubilized in Cell Extraction Buffer (BioSource International, Inc., USA) (10 mM Tris, pH 7.4, 0.1% SDS, 10% glycerol) supplemented with Protease Inhibitor cocktail and phosphatase inhibitor cocktail both at the final concentration of 1 mM (Sigma-Aldrich). Protein concentrations were measured with the BCA protein Assay Kit (Pierce, Rockford, USA). Total protein (15 μg) was separated by SDS-PAGE (12%) and then transferred onto PVDF membranes. Membranes were quenced in Blotto A buffer (Santa Cruz Biotechnology Inc., CA, USA) and then incubated with specific primary antibody (Santa Cruz Biotechnology Inc.) for DLX3 protein (1:100). The blots were washed in TBST buffer (Tween-20 0.05%) (Santa Cruz Biotechnology Inc.) then incubated with horseradish peroxidase-conjugated secondary antibody (HRP) (1:2000) (Santa Cruz Biotechnology Inc.). The Enhanced chemiluminescence (ECL) Kit (GE Healthcare, UK) was used to visualize immunoreactivity. ß-actin was used as housekeeping control. Gels were imaged using a high-resolution scanner (Arcus II, Agfa). The BAP (Brightness Area Product) of the DLX3 bands was determined with a constant threshold after black/white inversion using the Adobe Photoshop 7 software (Adobe) (23) . The BAPs of DLX3 were plotted versus the known amount of DLX3 loaded and a standard curve was built. DLX3 BAP was normalized on the corresponding BAP value of the housekeeping protein ß-actin.
Statistical analysis. DLX3 gene expression levels for all patients were first compared considering DLX3 methylation status among them and applying the Dunn's Multiple comparison test to compare variances. Besides, DLX3 gene expression was compared among patients belonging to different leukemia genetic subtypes and applying the nonparametric Mann-Whitney t test. Fig. 2 and Table III) . SYBR Green real-time quantitative PCR on RS4;11 and REH cell lines upon treatment with the DNMT1 inhibitor 5-Aza-2'-dC, shows that DLX4, though methylated in cell lines but unmethylated in normal control samples (Fig. 2) , does not achieve a considerable increase of gene expression during demethylation (data not shown). Moreover, DLX2 not methylated in either AL cell lines and non-tumorigenic controls (Fig. 2) , is not considered as target for subsequent gene expression studies. Importantly and conversely to DLX2 and DLX4 genes, DLX3 expression is absent in untreated cell lines and dramatically increases after demethylation (2.00-E+06 in RS4;11 and 4.00-E+05 in REH cells -both after 72 h) (Fig. 3) .
Results
MSP and SYBR green RQ-PCR in normal controls and acute leukemia (AL) cell lines. DLX3 is methylated in cell lines but completely unmethylated in normal control samples (
MSP and SYBR green RQ-PCR in paediatric B-ALL.
We have analyzed the 5' sequence methylation status of DLX3 and the Table II . DLX3, DLX4 and GUSB primer sequences and quantity used for SYBR green RQ-PCR analysis.
-------------------------------------------------
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Fw, forward primer; Rv, reverse primer. (Table III) . The results of MSP reactions on the 5' region of DLX3 show the presence of methylated alleles in 50.84% (30/59) of the samples. In particular DLX3 is methylated in 70.58% (24/34) of MLL-AF4 patients and in 38.46% (5/13) of the non-translocated samples. Interestingly, DLX3 is almost unmethylated (11/12) in specimens with TEL-AML1 but methylated in leukemia derived cell lines (Fig. 2 and Table III) . Real-time quantitative PCR experiments underline that DLX3 methylation status significantly correlates to down-regulation of the gene in B-ALL paediatric patients (P<0.01) (Fig. 4A) . Furthermore, a high methylation incidence of DLX3 in MLL-AF4 positive cases is associated with significant down-regulation of expression as compared to specimens with TEL-AML1 (P=0.0007) (Fig. 4B) . Instead, DLX4 [clustered with DLX3 in the 17q21 locus (24, 25) ] which is unmethylated in healthy controls and methylated in 59.32% (35/59) of leukemic samples randomly divided over the three specific genetic groups of patients, does not demonstrate a significant methylation-dependent gene expression regulation (data not shown). The DLX2 5' region results unmethylated in both normal and leukemic samples (Fig. 2) thus denying the hypothesis of DLX2 as epigenetic marker in paediatric B-ALL and underlining the observation that methylation events are locus specific restricted here to the DLX3-4 locus. ONCOLOGY REPORTS 18: 417-423, 2007 Table III. Summary of samples used and corresponding MSP results. 
No., number of patients analysed; M, methylated; U, unmethylated; +, positive; -, negative. Western blot analysis for DLX3 protein on RS4;11 leukemic cell lines during demethylation treatment. Western blot experiments in the RS4;11 laeukemic cell lines (Fig. 5A) , where DLX3 gene expression highly increased during demethylating treatment, confirm that DLX3 gene expression down-regulation results also in protein down-regulation. In fact, the analysis shows that DLX3 protein expression differs between control experiments with RS4;11 cells and experiments with treated RS4;11 cells (Fig. 5B ) increasing in the latter in parallel with decreasing methylation.
Discussion
In a survey for aberrant methylation of DLX2, DLX3 and DLX4 genes in AL we analyzed cell lines presenting specific chromosomal translocations, fresh normal bone marrow and a normal cell line. First we found that DLX3 and 4 were methylated in AL cell lines and unmethylated in normal controls, contrary to DLX2 gene that resulted unmethylated in all cases. This observation prompted us to investigate if this epigenetic feature was related to functional inactivation. DLX3 gene expression greatly increased upon exposing leukemic cells to the demethylating agent 5-Aza-2'-deoxycytidine. This result proved that the methylation of DLX3 CpG islands at the 5' moiety, has a functional role and interferes with its expression in B-ALL cells. Also DLX3 protein expression increased with increasing demethylation confirming the functional role of DLX3 methylation on subsequent events. Since hypermethylation of CpG islands is a common phenomenon in several tumor types and in adult and paediatric ALL where it is associated with poor prognosis and specific patient subgroups (7), we decided to validate our in vitro gene expression data, studying two different groups of paediatric B-ALL. We investigated both DLX3 methylation and gene expression profiles in a genetic cohort of B-ALL carrying MLL-AF4 translocation: these patients are well known for both their poor prognosis and response to chemotherapy (16) . Further, we chose a group of paediatric B-ALL with the TEL-AML1 chromosomal aberration that represents a cohort of good prognosis patients (17) (18) (19) , and a control group of B-ALL without translocations. In B-ALL paediatric patients, DLX3 methylation status significantly correlates to its transcriptional inactivation; furthermore, according to its higher frequency of methylation, DLX3 expression is lower in MLL-AF4 cases as compared to those with TEL-AML1, suggesting that DLX3 aberrant methylation could be characteristic for this subgroup of patients and have a specific role in high-risk paediatric B-ALL. DLX3 unmethylated in specimens with TEL-AML1 rearrangement, is methylated in TEL-AML1 leukemia derived cell line probably reflecting the global derangement of the methylation machinery often observed in stabilized cell lines. Moreover these data suggest that methylation could be the reason for immortalization typical of cell lines. Importantly, in spite of the low DLX4 gene expression level in the methylated TEL-AML1 samples, we could not observe a statistically significant correspondence between the methylation status of DLX4 and its down-regulation, likely because of the small number of unmethylated samples present in our population. Even if methylation occurs in both DLX3 and DLX4 genes, which are situated in the same locus, and even if they are clustered genes with the same duplication origins (26), they are not co-regulated. This fact probably reflects specific regulatory events for both genes, and locus independent gene-specificity of methylation. Moreover, the opposite methylation pattern of DLX3 and DLX4 genes among the two genetic leukaemia subgroups studied, is a further confirmation of the heterogeneity of hypermethylation in leukemia and of the power of hypermethylation to discriminate different genetic and clinical subgroups of patients (7) .
Overall survival analysis of the paediatric B-ALL cohort studied here and in particular of MLL-AF4 patients showed a trend of reduced survival chances in patients characterized by the methylation of DLX3 5' region as compared to those with unmethylated ones. However, there is no statistic significance probably because of the small number of patients (data not shown). These data suggests that the methylation of DLX3 could be responsible for the shorter overall survival of this class of paediatric B-ALL.
The downward trend of survival for DLX3-methylated cases and the high percentage of DLX3 methylation in MLL-AF4 paediatric patients, who respond poorly to therapy, may well be related to the previously suggested (14) contribution of DLX3 down-regulation to resistance to apoptosis. The role of DLX3 down-regulation could be similar to that previously reported for CD10 for high-risk pediatric B-ALL (27) . The epigenetic importance of DLX3 is sustained by the observation that MLL-AF4 paediatric patients have a high incidence of silenced genes frequently methylated in haematological malignances, that when re-expressed contribute to cell toxicity (28) . As previously reported in other studies (10) , it is difficult to establish if the downregulation of DLX3 methylation is a key event in immature B-cell leukemiogenesis or whether DLX3 hypermethylation is a consequence of MLL rearrangement. The MT domain common to all MLL fusion proteins, binds specifically unmethylated CpG sequences (29) : the first result could be the constant activation of target genes and DLX3 hypermethylation could be part of a machinery that acts to balance this altered situation. Again, the binding of MLL domain could inhibit the activity of DNA-binding proteins such as transcription factors, thus resulting in a suppressor effect. In this way, DLX3 methylation could be a downstream effect of an MLL-AF4 target gene. Similar to PML-RAR fusion protein in positive acute promyelocytic leukemia (11) , the binding of MLL-AF4 fusion proteins to specific DNA region could be responsible of the recruiting of DNA methyltransferases to hypermethylate the promoter region of downstream targets among which DLX3.
In conclusion, our results show for the first time the aberrant methylation of DLX3 gene and its functional inactivation in the specific cohort of paediatric B-ALL with the MLL-AF4 chromosomal aberration. This finding proposes DLX3 as a new epigenetic candidate marker involved in leukemiogenesis of this high-risk acute lymphoblastic leukemia.
